Is Statin-Induced Myositis Part of the Polymyositis Disease Spectrum?

  • Jemima Albayda
  • Andrew L. MammenEmail author
Inflammatory Muscle Disease (RG Cooper, Section Editor)
Part of the following topical collections:
  1. Topical Collection on Inflammatory Muscle Disease


Statin medications have recently been shown to cause not only a toxic myopathy but also an immune-mediated necrotizing myositis. Before the discovery of a specific anti-HMG-CoA reductase antibody occurring in conjunction with a necrotizing myopathy, many of these patients may have been classified as polymyositis. They present similarly with proximal muscle weakness, elevated muscle enzymes, persistence of symptoms despite cessation of the statin, with need for immunosuppression. This article provides an overview of this novel disease entity by placing it in the context of existing idiopathic inflammatory myopathy (IIM) classification criteria, and in the range of statin-associated muscle toxicity.


Statin myopathy Anti-HMG CoA reductase Polymyositis Necrotizing myopathy Classification criteria IMNM 


Compliance With Ethics Guidelines

Conflict of Interest

Jemima Albayda declares that she has no conflict of interest. Andrew L. Mammen reports grants from NIH during the conduct of the study. In addition, Dr Mammen has patented an anti-HMGCR antibody test from which he is entitled to receive royalties from INOVA Diagnostics.

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by any of the authors.


Papers of particular interest, published recently, have been highlighted as: • Of importance

  1. 1.
    Bohan A, Peter JB. Polymyositis and dermatomyositis (first of two parts). N Engl J Med. 1975;292(7):344–7.PubMedCrossRefGoogle Scholar
  2. 2.
    Bohan A, Peter JB. Polymyositis and dermatomyositis (second of two parts). N Engl J Med. 1975;292(8):403–7.PubMedCrossRefGoogle Scholar
  3. 3.
    Hoogendijk JE, Amato AA, Lecky BR, Choy EH, Lundberg IE, Rose MR, et al. 119th ENMC international workshop: Trial design in adult idiopathic inflammatory myopathies, with the exception of inclusion body myositis, 10–12 October 2003, Naarden, The Netherlands. Neuromuscul Disord. 2004;14(5):337–45.PubMedCrossRefGoogle Scholar
  4. 4.
    Dalakas M. Polymyositis, dermatomyositis and inclusion body myositis. N Engl J Med. 1991;325(21):1487–98.PubMedCrossRefGoogle Scholar
  5. 5.
    Kissel JT, Mendell JR, Rammohan KW. Microvascular Deposition of Complement Membrane Attack Complex in Dermatomyositis. N Engl J Med. 1986;314(6):329–34.PubMedCrossRefGoogle Scholar
  6. 6.
    Arahata K, Engel AG. Monoclonal antibody analysis of mononuclear cells in myopathies. I: Quantitation of subsets according to diagnosis and sites of accumulation and demonstration and counts of muscle fibers invaded by T cells. Ann Neurol. 1984;16(2):193–208.PubMedCrossRefGoogle Scholar
  7. 7.
    Emslie-Smith A, Arahata K, Engel AG. Major histocompatibility complex class 1 antigen expression, immunolocalization of interferon subtypes, and T cell-mediated cytotoxicity in myopathies. Hum Pathol. 1989;20(3):224–31.PubMedCrossRefGoogle Scholar
  8. 8.
    Tanimoto K, Nakano K, Kano S, Mori S, Ueki H, Nishitani H, et al. Classification criteria for polymyositis and dermatomyositis. J Rheumatol. 1995;22(4):668–74.PubMedGoogle Scholar
  9. 9.
    Linklater H, Pipitone N, Rose M, Norwood F, Campbell R, Salvarani C, et al. Classifying idiopathic inflammatory myopathies: comparing the performance of six existing criteria. Clin Exp Rheumatol. 2013;31(5):767–9.PubMedGoogle Scholar
  10. 10.
    Fernandez C, Bardin N, De Paula AM, Salort-Campana E, Benyamine A, Franques J, et al. Correlation of Clinicoserologic and Pathologic Classifications of Inflammatory Myopathies: Study of 178 Cases and Guidelines for Diagnosis. Medicine (Baltimore). 2013;92(1):15–24.CrossRefGoogle Scholar
  11. 11.
    Troyanov Y, Targoff IN, Tremblay J-L, Goulet J-R, Raymond Y, Senecal J-L. Novel Classification of Idiopathic Inflammatory Myopathies Based on Overlap Syndrome Features and Autoantibodies: Analysis of 100 French Canadian Patients. Medicine (Baltimore). 2005;84(4):231–49.CrossRefGoogle Scholar
  12. 12.
    Targoff IN, Miller FW, Medsger TA, Oddis CV. Classification criteria for the idiopathic inflammatory myopathies. Curr Opin Rheumatol. 1997;9(6):527–35.PubMedCrossRefGoogle Scholar
  13. 13.•
    Preuße C, Goebel HH, Held J, Wengert O, Scheibe F, Irlbacher K, et al. Immune-Mediated Necrotizing Myopathy Is Characterized by a Specific Th1-M1 Polarized Immune Profile. Am J Pathol. 2012;181(6):2161–71. This study demonstrated that a difference in cellular and molecular characteristics can distinguish immune-mediated necrotizing myopathies from non-immune-mediated necrotizing myopathies.PubMedCrossRefGoogle Scholar
  14. 14.
    Tansley SL, Betteridge ZE, McHugh NJ. The diagnostic utility of autoantibodies in adult and juvenile myositis. Curr Opin Rheumatol. 2013;25(6):772–7.PubMedCrossRefGoogle Scholar
  15. 15.
    Ghirardello A, Bassi N, Palma L, Borella E, Domeneghetti M, Punzi L, et al. Autoantibodies in Polymyositis and Dermatomyositis. Curr Rheumatol Rep [Internet]. 2013. [cited 2014 May 21];15(6). Available from:  10.1007/s11926-013-0335-1
  16. 16.
    Cruellas M, Viana V, Levy-Neto M, Souza F, Shinjo S. Myositis-specific and myositis-associated autoantibody profiles and their clinical associations in a large series of patients with polymyositis and dermatomyositis. Clinics. 2013;68(7):909–14.PubMedCentralPubMedCrossRefGoogle Scholar
  17. 17.
    Christopher-Stine L, Casciola-Rosen LA, Hong G, Chung T, Corse AM, Mammen AL. A novel autoantibody recognizing 200-kd and 100-kd proteins is associated with an immune-mediated necrotizing myopathy. Arthritis Rheum. 2010;62(9):2757–66.PubMedCentralPubMedCrossRefGoogle Scholar
  18. 18.
    Tansley S, Gunawardena H. The Evolving Spectrum of Polymyositis and Dermatomyositis—Moving Towards Clinicoserological Syndromes: A Critical Review. Clin Rev Allergy Immunol [Internet]. 2013. [cited 2014 Mar 1]; Available from: 10.1007/s12016-013-8387-6
  19. 19.
    Van der Meulen MFG, Bronner IM, Hoogendijk JE, Burger H, van Venrooij WJ, Voskuyl AE, et al. Polymyositis: An overdiagnosed entity. Neurology. 2003;61(3):316–21.PubMedCrossRefGoogle Scholar
  20. 20.
    Milisenda JC, Selva-O’Callaghan A, Grau JM. The diagnosis and classification of polymyositis. J Autoimmun [Internet]. 2014 [cited 2014 Mar 1]; Available from:
  21. 21.
    Harris LJ, Thapa R, Brown M, Pabbathi S, Childress RD, Heimberg M, et al. Clinical and laboratory phenotype of patients experiencing statin intolerance attributable to myalgia. J Clin Lipidol. 2011;5(4):299–307.PubMedCrossRefGoogle Scholar
  22. 22.
    Bruckert E, Hayem G, Dejager S, Yau C, Bégaud B. Mild to Moderate Muscular Symptoms with High-Dosage Statin Therapy in Hyperlipidemic Patients —The PRIMO Study. Cardiovasc Drugs Ther. 2006;19(6):403–14.CrossRefGoogle Scholar
  23. 23.
    Law M, Rudnicka AR. Statin Safety: A Systematic Review. Am J Cardiol. 2006;97(8):S52–60.CrossRefGoogle Scholar
  24. 24.
    Graham DJ, Staffa JA, Shatin D, et al. INcidence of hospitalized rhabdomyolysis in patients treated with lipid-lowering drugs. JAMA. 2004;292(21):2585–90.PubMedCrossRefGoogle Scholar
  25. 25.
    Mammen A, Amato AA. Statin myopathy: a review of recent progress. Curr Opin Rheumatol. 2010;22(6):644–50.PubMedCrossRefGoogle Scholar
  26. 26.
    Sirvent P, Mercier J, Lacampagne A. New insights into mechanisms of statin-associated myotoxicity. Curr Opin Pharmacol. 2008;8(3):333–8.PubMedCrossRefGoogle Scholar
  27. 27.
    SLCO1B1 Variants and Statin-Induced Myopathy — A Genomewide Study. N Engl J Med. 2008;359(8):789–99.Google Scholar
  28. 28.
    Grable-Esposito P, Katzberg HD, Greenberg SA, Srinivasan J, Katz J, Amato AA. Immune-mediated necrotizing myopathy associated with statins. Muscle Nerve. 2010;41(2):185–90.PubMedGoogle Scholar
  29. 29.
    Needham M, Fabian V, Knezevic W, Panegyres P, Zilko P, Mastaglia FL. Progressive myopathy with up-regulation of MHC-I associated with statin therapy. Neuromuscul Disord. 2007;17(2):194–200.PubMedCrossRefGoogle Scholar
  30. 30.
    Goldman J, Fishman A, Lee J, Johnson R. The role of cholesterol-lowering agents in drug-induced rhabdomyolysis and polymyositis. Arthritis Rheum. 1989;32(3):358–9.PubMedCrossRefGoogle Scholar
  31. 31.
    Schalke B, Schmidt B, Toyka K, Hartung H. Pravastatin-Associated Inflammatory Myopathy. N Engl J Med. 1992;327(9):649–50.PubMedGoogle Scholar
  32. 32.
    Giordano N, Senesi M, Mattii G, Battisti E, Villanova M, Gennari C. Polymyositis associated with simvastatin. Lancet. 1997;349(9065):1600–1.PubMedCrossRefGoogle Scholar
  33. 33.•
    Mammen AL, Chung T, Christopher-Stine L, Rosen P, Rosen A, Doering KR, et al. Autoantibodies against 3-hydroxy-3-methylglutaryl-coenzyme A reductase in patients with statin-associated autoimmune myopathy. Arthritis Rheum. 2011;63(3):713–21. This study identified the autoantigen involved in statin-associated autoimmune myopathy and provided a mechanistic link between the drug and development of sustained autoimmunity.PubMedCentralPubMedCrossRefGoogle Scholar
  34. 34.•
    Mammen AL, Pak K, Williams EK, Brisson D, Coresh J, Selvin E, et al. Rarity of anti-3-hydroxy-3-methylglutaryl-coenzyme A reductase antibodies in statin users, including those with self-limited musculoskeletal side effects. Arthritis Care Res. 2012;64(2):269–72. This study demonstrated that anti-HMGCR is infrequently seen in patients who take statins, including those with self-limited statin intolerance, and is specific for an autoimmune myopathy.CrossRefGoogle Scholar
  35. 35.•
    Mammen AL, Gaudet D, Brisson D, Christopher-Stine L, Lloyd TE, Leffell MS, et al. Increased frequency of DRB1*11:01 in anti-HMG-CoA reductase-associated autoimmune myopathy. Arthritis Care Res. 2012;1233–7. This study identified class II HLA loci that confer susceptibility to and protection from anti-HMGCR myopathy. Google Scholar
  36. 36.
    Werner JL, Christopher-Stine L, Ghazarian SR, Pak KS, Kus JE, Daya NR, et al. Antibody levels correlate with creatine kinase levels and strength in anti-3-hydroxy-3-methylglutaryl-coenzyme A reductase-associated autoimmune myopathy. Arthritis Rheum. 2012;64(12):4087–93.PubMedCentralPubMedCrossRefGoogle Scholar
  37. 37.
    Cabot RC, Harris NL, Rosenberg ES, Shepard J-AO, Cort AM, Ebeling SH, et al. Case 37-2012: A 21-Year-Old Man with Fevers, Arthralgias, and Pulmonary Infiltrates. N Engl J Med. 2012;367(22):2134–46.CrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2014

Authors and Affiliations

  1. 1.Johns Hopkins University School of MedicineBaltimoreUSA
  2. 2.Johns Hopkins Bayview Medical CenterJohns Hopkins Myositis CenterBaltimoreUSA

Personalised recommendations